The mechanism by which the angiotensin I (AI) converting enzyme inhibitor SQ20,881 (<Glu-Trp-Pro-Arg-Pro-Gln-Ile-Pro-Pro) blocks the pressor response to exogenous AI was studied in mo in the intact anesthetized dog. When administered as a single dose 250 times that of Injected AI (250 nmoles/kg) into either the pulmonary or systemic circulation, SQ20,881 produced inhibition of pulmonary conversion of exogenous AI to AH that lasted for more than 6 hours as judged by the absence of immunoreactive or labeled AH in the pulmonary venous effluent. In contrast, the pressor response to exogenous AI began to reappear within 1 hour of SQ20.881 administration. Six hours following SQ20.881, the pressor response to AI had nearly returned to normal, still in the absence of demonstrable intrapulmonary conversion and without release of detectable amounts of All into the pulmonary venous effluent. These experiments demonstrated that AI has a pressor effect in the presence of SQ20.881 that is independent of pulmonary conversion. Studies with (DesAsp The nonapeptide SQ20.881 (<Glu-Trp-Pro-Arg-ProGln-Ile-Pro-Pro) is a potent and long-lasting competitive inhibitor of angiotensin I converting enzyme in vivo and in vitro. 5 "* Previous studies from our laboratory have shown that SQ20.881 inhibits both the acute pressor response and the generation of All seen immediately after the injection of AI into the pulmonary circulation of the dog.' Because of the importance of converting enzyme inhibitors such as SQ2O.881 as tools for elucidating the role of the reninangiotensin system in normal circulatory homeostasis and in the pathophysiology of hypertension, further studies of the mechanism of antihypertensive action of SQ20.881 were undertaken. The time course of converting enzyme inhibition by a single dose of SQ20.881 was evaluated in the pulmonary circulation of the intact dog. The pressor response to injected AI returned before demonstrable intrapulmonary conver- 
The nonapeptide SQ20.881 (<Glu-Trp-Pro-Arg-ProGln-Ile-Pro-Pro) is a potent and long-lasting competitive inhibitor of angiotensin I converting enzyme in vivo and in vitro. 5 "* Previous studies from our laboratory have shown that SQ20.881 inhibits both the acute pressor response and the generation of All seen immediately after the injection of AI into the pulmonary circulation of the dog.' Because of the importance of converting enzyme inhibitors such as SQ2O.881 as tools for elucidating the role of the reninangiotensin system in normal circulatory homeostasis and in the pathophysiology of hypertension, further studies of the mechanism of antihypertensive action of SQ20.881 were undertaken. The time course of converting enzyme inhibition by a single dose of SQ20.881 was evaluated in the pulmonary circulation of the intact dog. The pressor response to injected AI returned before demonstrable intrapulmonary conver- The t-butyloxycarbonyl derivative of d-asparatic acid was prepared as a custom synthesis by Bachem, Inc.; the t-butyloxydichlorobenzyl tyrosine was purchased from Bachem, Inc., and the other amino acids, including t-butyloxycarbonyl aspartic acid, t-amyloxycarbonyl tosyl arginine and t-butyloxycarbonyl tosyl histidine, were obtained from Beckman. We used t-butyloxycarbonyl tosyl histidine to minimize racemization. 12 - 1J The subsequent steps in synthesis and purification of the peptides were the same as those described previously. 1 Final yields of the purified peptide were 35-40%. The converting enzyme blocker SQ20,881 was a gift from the Squibb Institute for Medical Research.
Bioassay
The blood pressure responses to (D-Asp I by the chloramine-T method of Greenwood et al. u as modified by Nielsen et al. 15 The details of the iodination procedure and the purification of the monoiodinated peptides on columns of DEAE Sephadex A-25 have been described previously. 1 * Over 95% of the labeled material eluted from the columns was monoiodinated peptide with an estimated specific activity of 700 mc//*mole. The monoiodinated peptides were either used immediately or frozen with human serum albumin (1 mg/ml) and stored at -20° C. ) All were subjected to radioimmunoassay with antibodies to AI 17 and All. 18 The amount of peptide required to produce 50% displacement of 1M I-AII from the antibody was determined and compared with the amount of All required to do so. The ratio represents percent cross-reactivity.
Preparation of Peptide Standards
To develop a system for distinguishing generated All from AI, (Des-Asp ) All and the products of circulating angiotensinases, peptide standards were"" prepared as described previously. 16 Monoiodinated AI and All were incubated with trypsin, chymotrypsin or leucine aminopeptidase and each reaction mixture was subjected to high-voltage paper electrophoresis or column chromatography on DEAE Sephadex A-25. The (DesAsp All. All of the peptides generated in the in vivo studies could be identified by comparison with these standards.
In Vivo Studies
Twenty-two mongTel dogs of both sexes weighing 20-30 kg were anesthetized with sodium pentobarbital (20 mg/kg, I.V.), received a tracheostomy, and were placed on a Harvard respirator. Each animal was given heparin (1000 U/kg, I.V.). A Swan-Ganz catheter was advanced into the pulmonary artery, as verified by the contour of the pressure tracing, and then withdrawn until a typical right ventricular pressure tracing was obtained. The catheter was left in the right ventricle for the remainder of the experiments. Large-bore retrograde catheters were placed in the ascending aorta and the abdominal aorta. Blood pressure was continuously monitored from the catheter in the abdominal aorta by a Statham pressure transducer and recorded on an Electronics for Medicine photographic recorder.
Then SQ20,881 (5 ^moles total dose, or 0.25 mg/kg) was injected as a single bolus into the right ventricle of 16 dogs followed in 30 seconds and at 30, 60, 90 and 120 minutes by a second bolus of either unlabeled AI (20 nmoles) or 12e I-AI (100 pmoles or 1 X 10" counts/min). This dose of 1M I-AI gave a concentration of iodinated peptide in aortic plasma that approached physiological levels (1 X 10* counts/min ml tion of unlabeled AI, a 5-nmole bolus of unlabeled All was injected into the right ventricle to evaluate pressor responsiveness to All. In four animals, additional injections of unlabeled AI or 115 I-AI were made at 3, 4 and 6 hours following SQ2O,881. In six experiments, SQ20.881 (5 Mmoles total dose, or 0.25 mg/kg) was injected into the ascending aorta at time 0, and unlabeled AI or 1J6 I-AI was injected into the right ventricle at intervals as previously described. In this way, the effects of systemic and pulmonary administration of the inhibitor were compared.
Bolus injections of either 20 or 100 nmoles of unlabeled (Des-Asp ) All were administered into the right ventricle of four animals to evaluate pressor activity, immunologic activity and metabolic products of the two peptides in vivo.
After injection of each peptide into the right ventricle, blood was collected in five sequential 7-ml samples from the ascending aorta at 5-second intervals into syringes containing dimercaprol, 8-OH quinoline and EDTA and the plasma fraction separated and stored as previously described." Plasma samples containing unlabeled peptides were subjected to radioimmunoassay for AI 17 and AIL 18 Radioactive samples were subjected to high-voltage paper electrophoresis and column chromatography on DEAE Sephadex A-25 for identification and quantification of labeled peptides. 18 The second and third sequential samples obtained 5 to 15 seconds after injection represented one circulation through the lung as determined by the appearance time of radioactive material. These were subjected to the most detailed chemical and immunological analysis. At least 30 minutes were allowed to lapse between injections to avoid interference with residual radioactive and immunoreactive material. Abbreviations: Asp = aspartic acid; Arg = arginine; Val = valine; Tyr = tyrosine; lie = isoleucine; His = histidinyl; Pro = proline; Phe = phenylalanine; Leu = leucine; AI = angiotensin I; All = angiotensin II.
Results

Peptide Characterization
Amino acid analyses were performed on a Durrum analyzer after hydrolysis with 5.7 N HCL for 24 hours at 110° C. Acid hydrolysis yielded the amino acids in the expected ratios (table 1) . Each unlabeled peptide (10 ^g) or each iodinated peptide was subjected to descending paper chromatography followed by electrophoresis in a second dimension as previously described. 1 ' Each peptide produced a single spot with ninhydrin-collidine stain or a single labeled spot. The (D-Asp 1 , He 8 ) All was evaluated for racemization of D-Asp during synthesis by incubation with leucine aminopeptidase and for susceptibility to cleavage at the carboxyl terminus by incubation with carboxypeptidase A, as previously described. 1 ' There was no measurable L-aspartic acid at the amino terminus, and the molecule was susceptible to enzymatic cleavage at the carboxyl terminus.
Bioassay
In dogs anesthetized with sodium pentobarbital, a 5-^mole dose of (D-Asp 1 , He 8 ) All caused a rise in mean blood pressure of 9 ± 2 (SE) mm Hg; a 10-nmole dose of All caused a rise in mean blood pressure of 44 ± 6 mm Hg. Thus, the He 8 substituted peptide had approximately 1/2500th the pressor activity of All. The heptapeptide (Des-Asp 1 ) All had 25% and the hexapeptide (Des-Asp 1 , Arg 2 ) All had 1% of the pressor potency of an equimolar amount of All. In doses up to 1 mg/kg, SQ2O.881 had no effect on resting blood pressure or on the pressor response to exogenous All.
Radioimmunoassay
The concentration of each peptide at 50% displacement and the percent cross-reactivity are summarized in table 2. The cross-reactivity of hepta-and hexapeptides with anti-All was 20% and 25%, respectively. This was sufficient to allow detection of pressor doses of both peptides in aortic blood by radioimmunoassay using anti-All and 12 *I-AII. In a concentration 1000 times that of AI or All, SQ20.881 did not cross react with either anti-AI or anti-All.
In Vivo Studies Figure 2 represents a typical response of blood pressure to injection of SQ20,881 followed by AI. Angiotensin I alone produced a mean increase of 52 ± 5 (SE) mm Hg in systolic pressure and 39 ± 3 mm Hg in diastolic pressure. SQ2O,881 acutely abolished the pressor response to AI, but it did not lower baseline blood pressure. Responsiveness to the pressor effects of AI gradually returned toward normal. Mean pressor response to a 20-nmole dose of AI at 60 minutes was 25 ± 3 mm Hg systolic and 23 ± 4 mm Hg diastolic; at 120 minutes, 29 ± 4 mm Hg systolic and 23 ± 4 mm Hg diastolic. The pressor response to 5 nmoles of administered All was 27 ± 3 mm Hg systolic and 21 ± 4 mm Hg diastolic. Prior administration of SQ20.881 did not alter the pressor response to All. Intraaortic injection of SQ2O.881 produced the same complete inhibition of the acute pressor response to AI as intrapulmonary injection. Recovery of the pressor response took place over a similar time course. In the four experiments that were carried out up to 6 hours after SQ20,881 administration, the pressor response to 20 nmoles of AI reached a peak of 48 ± 3 mm Hg systolic and 44 ± 2 mm Hg diastolic (92% and 113% of baseline, respectively) at 6 hours. Neither the systolic nor the diastolic pressor response to AI was significantly different from baseline. The pressor response to All did not change over time.
Injection of 5 ^moles of (D-Asp 1 , He') All blocked both the immediate pressor response to AI and All and the delayed pressor response to AI following injection of SQ20,881, but it did not alter the conversion of AI to All (table 3) . This result supports the All dependence of all of the observed pressor effects. Table 4 summarizes the pressor responses and concentrations of immunoreactive AI and All in aortic blood 5 to 15 seconds following injection of AI before and at intervals after administration of SQ20,881. Pulmonary conversion of AI as judged by appearance of immunoreactive All in the pulmonary venous effluent was blocked by SQ20.881 and did not return by 6 hours following administration of the nonapep- tide inhibitor, even after the pressor response had returned. Similar results were obtained following intraaortic injection of SQ20,881. Figure 3 illustrates the results of a representative experiment with 128 I-AI. Within 5 to 15 seconds after intrapulmonary injection of 12 *I-AI alone, 70% of the labeled material appearing in aortic blood after a single circulation time was All; 10% was intact AI, and 20% was accounted for by peptide metabolites. These included Tyr, the (3-10) peptide and the (1-4) peptide. Because of the small molar quantity injected, no pressor response was seen. After injection of SQ20,881 into either the right ventricle or the aorta, no 125 I-AI was converted to 128 I-AII in the pulmonary circulation. Furthermore, no labeled All appeared at 30, 60 or 120 minutes after SQ2O.881 injection. The (Des-Asp 1 ) All and (Des-Asp 1 , Arg 2 ) All peptides did not appear in the pulmonary effluent following administration of 128 I-AI alone or at any time interval after SQ20,881. Table 5 summarizes the results of all  experiments with 1M I-AI.
FIGURE 2. Pressor responses after injection of AI (20 nmoles) or of SQ20.881 into the right ventricle followed at intervals by second injections of AI. The arrows represent times of injection. Paper speed
Injection of (Des-Asp 1 ) All or (Des-Asp 1 , Arg 2 ) All into the pulmonary circulation yielded results that are summarized in table 6. The pressor responses to (Des-Asp 1 ) All and (Des-Asp 1 , Arg 2 ) All were approximately 25% and 1% of the responses to equimolar amounts of All, respectively. Apparent concentrations of All in aortic blood were estimated by radioimmunoassay with anti-All antiserum. Within 5 to 15 seconds following injection of (DesAsp 1 ) All, the apparent All concentration in the pulmonary effluent was 20% of that predicted from an equimolar dose of injected All; following (Des-Asp 1 , Arg 2 ) All, 25% of the predicted concentration. These data are consistent with our bioassay data and with our in vitro cross-reactivity studies using anti-All antiserum (table 1) . The experiments gave evidence that the returning pressor response to AI following injection of SQ20.881 is not due to the generation of (Des-Asp 1 ) All or (Des-Asp 1 , Arg 2 ) All, the only fragments of All that have been shown to have pressor activity. 
Discussion
This study has delineated the time course of AI converting enzyme inhibition and of blockade of the pressor response to pharmacologic doses of injected AI by a single dose of SQ20.881 administered into either the pulmonary circulation or the systemic circulation of the intact anesthetized dog. The pressor response to injected AI returned before demonstrable intrapulmonary conversion of AI as judged by the appearance of immunoreactive All in aortic blood.
The response to SQ2O.881 was the same whether the blocker was introduced into the pulmonary or systemic circulation, suggesting that local destruction of SQ20.881 in a single passage through peripheral capillary beds was insufficient to decrease the extent or duration of pulmonary converting enzyme blockade.
The pressor response to AI injected into the pulmonary circulation gradually returned to 50% of control within 1 hour of SQ2O,881 administration. This is consistent with previous reports of a 60-to 90-minute blockade of the pressor response to exogenous No. AI in anesthetized 6 and conscious 19 dogs following administration of SQ20,881 in doses comparable to those used in our study. The degree and duration of inhibition by SQ20.881 of the Al-induced pressor response have been shown to be dose-related. 19 In our study, further increases in pressor responsiveness to AI occurred between 1 and 6 hours after SQ20,881, approaching pre-SQ20,881 levels by 6 hours. Hypovolemia did not appear to be responsible, since care was taken to fully replace blood loss with normal saline. Plasma renin activity and endogenous circulating All did not increase with time following SQ20,881 administration in these animals. Furthermore, the pressor response to injections of All administered 1 to 6 hours following SQ20.881 did not differ from the response to control injections, indicating that the failure of the AI pressor response to return to control levels was not due to refractoriness to All or nonspecific unresponsiveness of the preparation to pressor substances. The long-lasting diminution in the pressor response to injected AI following SQ20,881 administration therefore appeared to be due to impaired production of All.
Minute amounts (< 1 pmole/ml above control) of material that reacted with anti-All antiserum appeared in aortic blood following AI injection within 6 hours of SQ20.881 administration. A portion of this increase in apparent All concentration represents cross-reactivity of anti-All antiserum with circulating AI and its metabolites. The remainder may result from a small amount of residual intrapulmonary conversion of AI. It should be noted that the apparent All concentration in the pulmonary effluent did not increase with time and did not parallel the return of the pressor response to AI. Furthermore, the amount of All generated was far too small to account for the observed pressor response. When 115 I-AI was administered in near-physiologic doses into the pulmonary circulation, no 1M I-AII appeared in aortic blood. This confirms the results of studies with pharmacologic doses of unlabeled AI and suggests that the duration of pulmonary converting enzyme inhibition by SQ20,881 is greater than the duration of its major antihypertensive action. The data indicate that AI in pharmacologic doses has a pressor effect in the presence of SQ20,881 that is independent of demonstrable intrapulmonary conversion. Possible explanations include: 1) pressor effects of circulating peptide metabolites of AI or All; 2) extrapulmonary conversion of AI to All; and 3) an independent pressor effect of AI, either direct or mediated by the central nervous system or adrenal medullary catecholamines. To investigate the first possibility, (Des-Asp 1 ) All and (Des-Asp 1 , Arg 2 ) All, the only peptide fragments of AI or All that have pressor activity, 20 
"
22 were synthesized, labeled with 12i I and evaluated for immunologic activity with anti-All antisemm and for pressor activity in the closed chest anesthetized dog. Results indicated that both the pressor and immunologic activities of (Des-Asp 1 ) All and the immunologic activity of (Des-Asp 1 , Arg 2 ) All were reduced to 20-25% of an equimolar quantity of All; the pressor activity of (Des-Asp 1 , Arg 2 ) All was only 1% of AIL Thus a substantial pressor response could not have been produced by either of these All derivatives in the absence of appreciable immunoreactive peptide in aortic blood. In addition, the heptaand hexapeptide derivatives of All were not found in aortic blood following the intrapulmonary administration of m I-AI. For all of these reasons, circulating metabolites of AI and All did not appear to account for the pressor response to AI observed in the presence of SQ2O.881.
To evaluate the All dependence of the pressor response to AI before and after administration of ) All is thought to be an antagonist of All, 1 ' these results suggest that the late pressor effect of pharmacologic doses of AI following administration of SQ20.881 is due to All generation in extrapulmonary sites. These data make an independent pressor effect of AI an unlikely explanation for this phenomenon.
Previous studies in which AI was administered into various peripheral capillary beds of the dog, including kidney, 24 ' M mesentcric circulation, 2 " hindlimb 27 and liver, 28 have given evidence that some AI conversion occurs in extrapulmonary sites. Also, the presence of all components of the renin-angiotensin system has been reported in isolated tissues not perfused with blood.
2 *' 1 Experiments in the rat have shown that the pressor response to exogenous All, 32 renin" or AI" was blocked more completely by SQ20,881 or the All antagonist (Sar 1 , Ala 8 ) All than by anti-All antiserum. These data have been interpreted as support for the hypothesis that All is generated at a site in blood vessel walls that is accessible to the readily diffusible converting enzyme or All antagonist but not to the large molecules of anti-All antibody. Similarly, SQ20,881 has been shown to lessen the vasoconstrictor effect of AI but not of All on human forearm vessels, suggesting that converting enzyme resides in the peripheral vessels of man."
The current study provides strong evidence that a single bolus of exogenous AI administered to the dog can be extensively and rapidly converted to All under conditions in which pulmonary conversion appears to be blocked by SQ20.881 without releasing detectable amounts of All into the circulation. The magnitude of the pressor response seen under these circumstances suggests that the systemic vascular bed as a whole may contain nearly as much converting enzyme as the lung. This had not been apparent in previous studies conducted in the absence of SQ20.881 because peripheral organ beds were studied individually and because the greater concentration of pulmonary converting enzyme and higher pulmonary blood flow caused pulmonary conversion to predominate. 2 u In the current study, a single injection of SQ20.881 totally blocked both pulmonary and peripheral conversion of exogenous AI for a brief time, but peripheral converting enzyme recovered more rapidly than the pulmonary enzyme. This may be explained in part by the greater accessibility of the blocker to pulmonary converting enzyme, which has been demonstrated on the luminal surface of pulmonary endothelial cells, 1 * than to peripheral converting enzyme. Additional possibilities are that SQ20.881 may be broken down more rapidly in the systemic than in the pulmonary circulation, or that there may be qualitative differences between pulmonary and peripheral converting enzyme(s). Further investigation will be needed to evaluate this problem and to identify the predominant site of conversion under physiological conditions.
